Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 28

Sort by

Sort Order Select

Meeting Abstracts

886-P: Response to Imeglimin for Japanese Patients with Type 2 Diabetes—Response Distribution Analysis of Individual Participant in Randomized Placebo-Controlled Trials

KATSUHIKO HAGI, KENJI KOCHI, HIROTAKA WATADA, KOHEI KAKU, KOHJIRO UEKI

Diabetes 2024;73(Supplement_1):886-P

https://doi.org/10.2337/db24-886-P

Published: 14 June 2024

View article titled, 886-P: Response to Imeglimin for Japanese Patients with Type 2 Diabetes—Response Distribution Analysis of Individual Participant in Randomized Placebo-Controlled Trials

Meeting Abstracts

1604-P: DPP-4 Inhibitor and SGLT2 Inhibitor Additively Ameliorate Hepatic Steatosis in NAFLD Model Mice through Different Action Mechanisms

YUICHIRO IWAMOTO, TOMOHIKO KIMURA, HIDEYUKI IWAMOTO, YOSHIRO FUSHIMI, JUNPEI SANADA, YUKINO KATAKURA, MASASHI SHIMODA, TOMOATSU MUNE, KOHEI KAKU, HIDEAKI KANETO

Diabetes 2023;72(Supplement_1):1604-P

https://doi.org/10.2337/db23-1604-P

Published: 20 June 2023

View article titled, 1604-P: DPP-4 Inhibitor and SGLT2 Inhibitor Additively Ameliorate Hepatic Steatosis in NAFLD Model Mice through Different Action Mechanisms

Meeting Abstracts

850-P: The Efficacy of Imeglimin in Diabetes Subgroups Stratified by Data-Driven Cluster Analysis—A Post Hoc Analysis of Imeglimin Clinical Trial Data

KATSUHIKO HAGI, KENJI KOCHI, HIROTAKA WATADA, KOHEI KAKU, KOHJIRO UEKI

Diabetes 2023;72(Supplement_1):850-P

https://doi.org/10.2337/db23-850-P

Published: 20 June 2023

View article titled, 850-P: The Efficacy of Imeglimin in Diabetes Subgroups Stratified by Data-Driven Cluster Analysis—A Post Hoc Analysis of Imeglimin Clinical Trial Data

Meeting Abstracts

886-P: Protective Effects of DPP-4 Inhibitor and SGLT2 Inhibitor on Pancreatic ß-Cell Function—Randomized, Parallel-Group, Multicenter, Open-Label Study (SECRETE-I)

MASASHI SHIMODA, YUKINO KATAKURA, MASAHIRO IWAMOTO, YUKIKO KIMURA, TAKATOSHI ANNO, HAYATO ISOBE, YUICHIRO IWAMOTO, YOSHIRO FUSHIMI, JUNPEI SANADA, ATSUSHI OBATA, TOMOHIKO KIMURA, FUMIKO KAWASAKI, FUMINORI TATSUMI, SHUHEI NAKANISHI, TOMOATSU MUNE, KOHEI KAKU, HIDEAKI KANETO

Diabetes 2023;72(Supplement_1):886-P

https://doi.org/10.2337/db23-886-P

Published: 20 June 2023

View article titled, 886-P: Protective Effects of DPP-4 Inhibitor and SGLT2 Inhibitor on Pancreatic ß-Cell Function—Randomized, Parallel-Group, Multicenter, Open-Label Study (SECRETE-I)

Meeting Abstracts

748-P: GLP-1 Receptor Agonists Dulaglutide and Semaglutide in Japanese Patients with Type 2 Diabetes—Randomized, Parallel-Group, Multicenter, Open-Label Trial

TOMOHIKO KIMURA, YUKINO KATAKURA, MASASHI SHIMODA, FUMIKO KAWASAKI, MIZUHO YAMABE, FUMINORI TATSUMI, MICHIHIRO MATSUKI, YUICHIRO IWAMOTO, TAKATOSHI ANNO, YOSHIRO FUSHIMI, SHINJI KAMEI, YUKIKO KIMURA, JUNPEI SANADA, YURIE HIRATA, SHUHEI NAKANISHI, TOMOATSU MUNE, KOHEI KAKU, HIDEAKI KANETO

Diabetes 2023;72(Supplement_1):748-P

https://doi.org/10.2337/db23-748-P

Published: 20 June 2023

View article titled, 748-P: GLP-1 Receptor Agonists Dulaglutide and Semaglutide in Japanese Patients with Type 2 Diabetes—Randomized, Parallel-Group, Multicenter, Open-Label Trial

Meeting Abstracts

794-P: Predictors of Hemoglobin (Hb) and Its Changes Focusing on Anemia and Polycythemia after Administration of the SGLT2 Inhibitor Tofogliflozin

YASUHIRO MATSUBAYASHI, AKIHIRO YOSHIDA, HIDEKI SUGANAMI, KOHEI KAKU, HIROHITO SONE

Diabetes 2021;70(Supplement_1):794-P

https://doi.org/10.2337/db21-794-P

Published: 01 June 2021

View article titled, 794-P: Predictors of Hemoglobin (Hb) and Its Changes Focusing on Anemia and Polycythemia after Administration of the SGLT2 Inhibitor Tofogliflozin

Meeting Abstracts

1133-P: Association of Higher Baseline BNP Levels with a Greater Reduction in Plasma Volume and Increase in Beta-Hydroxybutyrate via the SGLT2 Inhibitor Tofogliflozin in Type 2 Diabetes

AKIHIRO YOSHIDA, YASUHIRO MATSUBAYASHI, TOSHIAKI NOJIMA, HIDEKI SUGANAMI, MOMOKO OE, KAZUYA FUJIHARA, SHIRO TANAKA, KOHEI KAKU, HIROHITO SONE

Diabetes 2020;69(Supplement_1):1133-P

https://doi.org/10.2337/db20-1133-P

Published: 01 June 2020

View article titled, 1133-P: Association of Higher Baseline BNP Levels with a Greater Reduction in Plasma Volume and Increase in Beta-Hydroxybutyrate via the SGLT2 Inhibitor Tofogliflozin in Type 2 Diabetes

Meeting Abstracts

1125-P: Association of Plasma Volume with Body Weight and BNP after Long-Term Administration and Subsequent Withdrawal of the SGLT2 Inhibitor Tofogliflozin

YASUHIRO MATSUBAYASHI, AKIHIRO YOSHIDA, TOSHIAKI NOJIMA, HIDEKI SUGANAMI, KAZUYA FUJIHARA, KOHEI KAKU, HIROHITO SONE

Diabetes 2020;69(Supplement_1):1125-P

https://doi.org/10.2337/db20-1125-P

Published: 01 June 2020

View article titled, 1125-P: Association of Plasma Volume with Body Weight and BNP after Long-Term Administration and Subsequent Withdrawal of the SGLT2 Inhibitor Tofogliflozin

Meeting Abstracts

1435-P: Dulaglutide Exerts More Beneficial Antiatherosclerotic Effects in Early Phase of Diabetes than in Late Phase in ApoE Knockout Mice with Diabetes

JUNPEI SANADA, ATSUSHI OBATA, YOSHIYUKI OBATA, YOSHIRO FUSHIMI, TOMOKO IKEDA, YUKA NOGAMI, MASASHI SHIMODA, SHUHEI NAKANISHI, TOMOATSU MUNE, KOHEI KAKU, HIDEAKI KANETO

Diabetes 2020;69(Supplement_1):1435-P

https://doi.org/10.2337/db20-1435-P

Published: 01 June 2020

View article titled, 1435-P: Dulaglutide Exerts More Beneficial Antiatherosclerotic Effects in Early Phase of Diabetes than in Late Phase in ApoE Knockout Mice with Diabetes

Meeting Abstracts

2054-P: Combination of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor and Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Substantially Protects Pancreatic ß-Cells Especially in Early Phase of Diabetes Rather than Advanced Phase

YOSHIRO FUSHIMI, ATSUSHI OBATA, JUNPEI SANADA, YUKA NOGAMI, TOMOKO IKEDA, YOSHIYUKI OBATA, MASASHI SHIMODA, SHUHEI NAKANISHI, TOMOATSU MUNE, KOHEI KAKU, HIDEAKI KANETO

Diabetes 2020;69(Supplement_1):2054-P

https://doi.org/10.2337/db20-2054-P

Published: 01 June 2020

View article titled, 2054-P: Combination of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor and Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Substantially Protects Pancreatic ß-Cells Especially in Early Phase of Diabetes Rather than Advanced Phase

Meeting Abstracts

1219-P: Enhanced Response in Serum Ketone Level in Men Compared with Women by Administration of SGLT2 Inhibitor

AKIHIRO YOSHIDA, YASUHIRO MATSUBAYASHI, TOSHIAKI NOJIMA, HIDEKI SUGANAMI, KOHEI KAKU, HIROHITO SONE

Diabetes 2019;68(Supplement_1):1219-P

https://doi.org/10.2337/db19-1219-P

Published: 01 June 2019

View article titled, 1219-P: Enhanced Response in Serum Ketone Level in Men Compared with Women by Administration of SGLT2 Inhibitor

Meeting Abstracts

1205-P: Baseline Lactate Level Is a Useful Predictor for Weight Loss after Long-Term SGLT2 Inhibitor Treatment

TOSHIAKI NOJIMA, YASUHIRO MATSUBAYASHI, AKIHIRO YOSHIDA, HIDEKI SUGANAMI, KOHEI KAKU, HIROHITO SONE

Diabetes 2019;68(Supplement_1):1205-P

https://doi.org/10.2337/db19-1205-P

Published: 01 June 2019

View article titled, 1205-P: Baseline Lactate Level Is a Useful Predictor for Weight Loss after Long-Term SGLT2 Inhibitor Treatment

Meeting Abstracts

1215-P: Adipose Tissue Insulin Resistance Predicts Ketosis via an SGLT2 Inhibitor

YASUHIRO MATSUBAYASHI, AKIHIRO YOSHIDA, TOSHIAKI NOJIMA, HIDEKI SUGANAMI, KAZUYA FUJIHARA, KOHEI KAKU, HIROHITO SONE

Diabetes 2019;68(Supplement_1):1215-P

https://doi.org/10.2337/db19-1215-P

Published: 01 June 2019

View article titled, 1215-P: Adipose Tissue Insulin Resistance Predicts Ketosis via an SGLT2 Inhibitor

Meeting Abstracts

Reduced Postprandial Hepatic Insulin Clearance via the DPP-4 Inhibitor Anagliptin Contributed to Improvement in Hyperglycemia in Patients with Type 2 Diabetes Mellitus

YASUHIRO MATSUBAYASHI, TAKAHIRO ABE, SAYAKA MURAGISHI, AKIHIRO YOSHIDA, HIDEKI SUGANAMI, KENICHI FURUSAWA, TAKAHO YAMADA, KAZUYA FUJIHARA, SHIRO TANAKA, KOHEI KAKU, HIROHITO SONE

Diabetes 2018;67(Supplement_1):1176-P

https://doi.org/10.2337/db18-1176-P

Published: 01 July 2018

View article titled, Reduced Postprandial Hepatic Insulin Clearance via the DPP-4 Inhibitor Anagliptin Contributed to Improvement in Hyperglycemia in Patients with Type 2 Diabetes Mellitus

Meeting Abstracts

Protective Effects of SGLT2 Inhibitor Luseogliflozin on Pancreatic Beta Cells in Obese Diabetic db/db Mice—"The Earlier and Longer, the Better”

TOMOHIKO KIMURA, MASASHI SHIMODA, SHUHEI NAKANISHI, TOMOATSU MUNE, KOHEI KAKU, HIDEAKI KANETO

Diabetes 2018;67(Supplement_1):2111-P

https://doi.org/10.2337/db18-2111-P

Published: 01 July 2018

View article titled, Protective Effects of SGLT2 Inhibitor Luseogliflozin on Pancreatic Beta Cells in Obese Diabetic db/db Mice—"The Earlier and Longer, the Better”

Meeting Abstracts

The SGLT2 Inhibitor Tofogliflozin Reduces Weight in People with Type 2 Diabetes due to Fluid Loss Initially and to Lipolysis in Late

AKIHIRO YOSHIDA, HIROMI KUSAKABE, TOSHINARI TAKAMURA, KOHEI KAKU, HIDEKI SUGANAMI

Diabetes 2018;67(Supplement_1):1152-P

https://doi.org/10.2337/db18-1152-P

Published: 01 July 2018

View article titled, The SGLT2 Inhibitor Tofogliflozin Reduces Weight in People with Type 2 Diabetes due to Fluid Loss Initially and to Lipolysis in Late

Meeting Abstracts

Initial Beta-Hydroxybutyrate Elevation in Relation to Subsequent Weight Loss in Type 2 Diabetes via the SGLT2 Inhibitor Tofogliflozin

YUICHI SATO, KIYOHIDE NUNOI, KOHEI KAKU, AKIHIRO YOSHIDA, HIDEKI SUGANAMI

Diabetes 2018;67(Supplement_1):1156-P

https://doi.org/10.2337/db18-1156-P

Published: 01 July 2018

View article titled, Initial Beta-Hydroxybutyrate Elevation in Relation to Subsequent Weight Loss in Type 2 Diabetes via the SGLT2 Inhibitor Tofogliflozin

Meeting Abstracts

Influence of SGLT2 Inhibitor on Resting Heart Rate (RHR) and Factors Related to Its Changes

YASUHIRO MATSUBAYASHI, TOSHIAKI NOJIMA, AKIHIRO YOSHIDA, HIDEKI SUGANAMI, TAKAHO YAMADA, KAZUYA FUJIHARA, SHIRO TANAKA, KOHEI KAKU, HIROHITO SONE

Diabetes 2018;67(Supplement_1):1154-P

https://doi.org/10.2337/db18-1154-P

Published: 01 July 2018

View article titled, Influence of SGLT2 Inhibitor on Resting Heart Rate (RHR) and Factors Related to Its Changes

Meeting Abstracts

Effects of Different Types of Oral Glucose-Lowering Drugs on Hepatic Fat Accumulation and Liver Function in Japanese Subjects with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—A Randomized, Open-Label, 3-Arm Active-Control Study

TOMOE KINOSHITA, MASASHI SHIMODA, SHUHEI NAKANISHI, TOMOATSU MUNE, KOHEI KAKU, HIDEAKI KANETO

Diabetes 2018;67(Supplement_1):2050-P

https://doi.org/10.2337/db18-2050-P

Published: 01 July 2018

View article titled, Effects of Different Types of Oral Glucose-Lowering Drugs on Hepatic Fat Accumulation and Liver Function in Japanese Subjects with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—A Randomized, Open-Label, 3-Arm Active-Control Study

Journal Articles

Replication Study for the Association Between Four Loci Identified by a Genome-Wide Association Study on European American Subjects With Type 1 Diabetes and Susceptibility to Diabetic Nephropathy in Japanese Subjects With Type 2 Diabetes

Shiro Maeda, Shin-ichi Araki, Tetsuya Babazono, Masao Toyoda, Tomoya Umezono, Koichi Kawai, Masahito Imanishi, Takashi Uzu, Hirotaka Watada, Daisuke Suzuki, Atsunori Kashiwagi, Yasuhiko Iwamoto, Kohei Kaku, Ryuzo Kawamori, Yusuke Nakamura

Diabetes 2010;59(8):2075–2079

https://doi.org/10.2337/db10-0067

Published: 11 May 2010

View article titled, Replication Study for the Association Between Four Loci Identified by a Genome-Wide Association Study on European American Subjects With Type 1 Diabetes and Susceptibility to Diabetic Nephropathy in Japanese Subjects With Type 2 Diabetes

Includes: Supplementary data

NARROW

886-P: Response to Imeglimin for Japanese Patients with Type 2 Diabetes—Response Distribution Analysis of Individual Participant in Randomized Placebo-Controlled Trials

1604-P: DPP-4 Inhibitor and SGLT2 Inhibitor Additively Ameliorate Hepatic Steatosis in NAFLD Model Mice through Different Action Mechanisms

850-P: The Efficacy of Imeglimin in Diabetes Subgroups Stratified by Data-Driven Cluster Analysis—A Post Hoc Analysis of Imeglimin Clinical Trial Data

886-P: Protective Effects of DPP-4 Inhibitor and SGLT2 Inhibitor on Pancreatic ß-Cell Function—Randomized, Parallel-Group, Multicenter, Open-Label Study (SECRETE-I)

748-P: GLP-1 Receptor Agonists Dulaglutide and Semaglutide in Japanese Patients with Type 2 Diabetes—Randomized, Parallel-Group, Multicenter, Open-Label Trial

794-P: Predictors of Hemoglobin (Hb) and Its Changes Focusing on Anemia and Polycythemia after Administration of the SGLT2 Inhibitor Tofogliflozin

1133-P: Association of Higher Baseline BNP Levels with a Greater Reduction in Plasma Volume and Increase in Beta-Hydroxybutyrate via the SGLT2 Inhibitor Tofogliflozin in Type 2 Diabetes

1125-P: Association of Plasma Volume with Body Weight and BNP after Long-Term Administration and Subsequent Withdrawal of the SGLT2 Inhibitor Tofogliflozin

1435-P: Dulaglutide Exerts More Beneficial Antiatherosclerotic Effects in Early Phase of Diabetes than in Late Phase in ApoE Knockout Mice with Diabetes

2054-P: Combination of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor and Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Substantially Protects Pancreatic ß-Cells Especially in Early Phase of Diabetes Rather than Advanced Phase

1219-P: Enhanced Response in Serum Ketone Level in Men Compared with Women by Administration of SGLT2 Inhibitor

1205-P: Baseline Lactate Level Is a Useful Predictor for Weight Loss after Long-Term SGLT2 Inhibitor Treatment

1215-P: Adipose Tissue Insulin Resistance Predicts Ketosis via an SGLT2 Inhibitor

Reduced Postprandial Hepatic Insulin Clearance via the DPP-4 Inhibitor Anagliptin Contributed to Improvement in Hyperglycemia in Patients with Type 2 Diabetes Mellitus

Protective Effects of SGLT2 Inhibitor Luseogliflozin on Pancreatic Beta Cells in Obese Diabetic db/db Mice—"The Earlier and Longer, the Better”

The SGLT2 Inhibitor Tofogliflozin Reduces Weight in People with Type 2 Diabetes due to Fluid Loss Initially and to Lipolysis in Late

Initial Beta-Hydroxybutyrate Elevation in Relation to Subsequent Weight Loss in Type 2 Diabetes via the SGLT2 Inhibitor Tofogliflozin

Influence of SGLT2 Inhibitor on Resting Heart Rate (RHR) and Factors Related to Its Changes

Effects of Different Types of Oral Glucose-Lowering Drugs on Hepatic Fat Accumulation and Liver Function in Japanese Subjects with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—A Randomized, Open-Label, 3-Arm Active-Control Study

Replication Study for the Association Between Four Loci Identified by a Genome-Wide Association Study on European American Subjects With Type 1 Diabetes and Susceptibility to Diabetic Nephropathy in Japanese Subjects With Type 2 Diabetes

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only